Prostate cancer aggressiveness gene signatures for subjects of african or european decent
AssigneeWayne State University
InventorsIsaac J. Powell, Aliccia Bollig-Fischer, Greg Dyson
Life of this patent
Estimating the term…
Abstract
The use of genes or biomarkers to more accurately diagnose aggressive prostate cancer in men of African descent or European descent is provided. More specifically, the genes or biomarkers of the present invention can be used in diagnostic tests and methods to determine, qualify, and/or assess aggressive prostate cancer or status, for example, to diagnose or identify aggressive prostate cancer, in an individual, subject, or patient, such as men of African descent or men of European descent.
Claims23
A method for identifying a patient of African descent or European Descent as having or likely to have aggressive prostate cancer comprising the steps of:
- a) detecting expression levels in a biological sample from the subject of a group of prostate cancer driver genes, said genes comprising ADIPOQ, AKT1, ALOX12, ALOX15, ALOX15B, BMP2, CGA, CXCR4, CYP19A1, ERG, FASN, IL1B, IL6, IL8, NFKB1, PIK3C3, PIK3CA, PIK3R1, PLA2G2A, TGFB1, and TIMP3;
- b) determining a number of positive indications for aggressive prostate cancer by comparing the detected expression levels of each of the prostate cancer driver genes determined in step b to an expression threshold level for each prostate cancer driver gene;
- and
- c) identifying the patient as having or likely to have aggressive prostate cancer if there are more positive indications than a gene score threshold.
A method for identifying a gene score threshold value for aggressive prostate cancer in an subject of African descent or European descent comprising the steps of:
- a) obtaining a biological sample from a first group of subjects of African descent diagnosed with prostate cancer or a second group of subjects of European descent;
- b) detecting expression levels in the biological samples of a group of prostate cancer driver genes, said genes comprising ADIPOQ, AKT1, ALOX12, ALOX15, ALOX15B, BMP2, CGA, CXCR4, CYP19A1, ERG, FASN, IL1B, IL6, IL8, NFKB1, PIK3C3, PIK3CA, PIK3R1, PLA2G2A, TGFB1, and TIMP3;
- c) determining the expression threshold level for each prostate cancer driver gene in step b, wherein determining the expression threshold level for each gene comprises:
- 1) measuring the expression level of each prostate cancer driver gene in step b or biomarker thereof in a statistically significant number of samples from subjects of African descent;
- 2) determining the expression threshold level for each driver gene by recursive partitioning utilizing a defined aggressive phenotype and non-aggressive phenotype of prostate cancer;
- d) determining a number of positive indications for aggressive prostate cancer by comparing the detected expression level of each gene determined in step b) to the expression threshold level determined in step c) for each gene;
- and
- e) determining a gene score threshold using recursive partitioning of the positive indications of step d).
19-20. (canceled)
(canceled)
24-60. (canceled)
Dependencies are inferred from the claim text.